MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx (Nasdaq: MDXG) announced a restructuring to reduce annual operating expenses by approximately $40 million and expects a one-time $4 million restructuring charge in Q2 2026. The company eliminated the Chief Operating Officer role and plans additional commentary with Q1 2026 results in late April.
Management said Surgical will receive further investment while Wound Care is recovering slowly after the January 1 Medicare reimbursement reduction.
MiMedx Group (Nasdaq: MDXG) will sponsor and present at two leading wound care conferences: SAWC Spring 2026 (April 8–12, Charlotte) and DLS 2026 (April 8–11, Washington, D.C.).
Activities include sponsored symposia, multiple poster and oral clinical presentations, and exhibit booths to showcase peptide-based and placental allograft wound-care technologies.
MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX on March 23, 2026, a lyophilized placental allograft composed of two chorion layers with an intact intermediate layer.
The company said CHORIOFIX is its thickest product to date, designed to improve handling, positioning and suturing, and has been added to the prospective randomized CAMPAIGN trial to evaluate performance versus standard of care in non-healing diabetic foot ulcers.
MiMedx (Nasdaq: MDXG) launched AMNIOFIX Thyroid Shields, a DHACM allograft line for endocrine surgery designed to protect the recurrent laryngeal nerve and parathyroid glands after thyroidectomy.
The product is preconfigured for operating-room use, shelf-stable up to five years, manufactured with the PURION process, and supported by a retrospective single-center study showing a 76% reduction in 24-hour RLN damage (3.4% vs 14.4%, p<0.01).
MIMEDX (Nasdaq: MDXG) reported record 2025 results with Q4 net sales $118M (+27% YoY) and full-year net sales $419M (+20% YoY). Q4 GAAP net income was $15M and full-year net income was $49M. Adjusted EBITDA for Q4 was $29M (25% of net sales). Cash totaled $166M at year-end. The board authorized a $100M share repurchase over two years. For 2026 the company estimates net sales of $340–360M and adjusted EBITDA margin in the mid-to-high teens.
MiMedx (Nasdaq: MDXG) will report fourth quarter and full year 2025 operating and financial results after market close on Wednesday, February 25, 2026.
The senior management team will host a webcast and conference call beginning at 4:30 p.m. ET on February 25. A replay will be available on the company website for approximately 30 days.
MIMEDX (Nasdaq: MDXG) entered an exclusive distribution agreement with Summit Products Group on February 4, 2026 to add three 510(k) cleared surgical and wound-care products: Hydrelix, NovaForm, and G4Derm Plus.
The products include a soluble bovine collagen powder, a bioglass-collagen wound matrix, and a flowable peptide matrix designed to support wound healing and manage bioburden.
MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery. Together they appear in nearly 100 clinical and scientific publications, including seven randomized controlled trials, and are described as the industry’s most studied placental allografts.
The company highlighted broad clinical use across more than a dozen surgical specialties and credited employees for advancing its products and peer-reviewed evidence base.
MiMedx (Nasdaq: MDXG) entered an exclusive U.S. distribution agreement with Regen Lab USA to distribute RegenKit®-Wound Gel, an autologous PRP and autologous thrombin serum wound gel, on Dec 22, 2025. The product concentrates growth factors, platelets, plasma proteins and nutrients in a fibrin scaffold and removes iron-laden red blood cells.
RegenKit was approved by FDA in 2022 and is covered nationally by CMS/LCD for diabetic chronic wounds under HCPCS code G0465. MiMedx says the kit adds a differentiated autologous option to its Advanced Wound Care portfolio and that upcoming LCD implementation on Jan 1, 2026 strengthens its competitive position.
MiMedx (NASDAQ: MDXG) announced a peer-reviewed publication on Dec 19, 2025 in the Journal of Inflammation reporting in vitro findings for Purion processed dehydrated (DHACM) and lyophilized (LHACM) human amnion chorion membrane allografts.
The study found that DHACM and LHACM exhibit multifactorial immunomodulatory effects on inflammatory monocytes and macrophages and enhance pro-reparative functions including efferocytosis and cell survival, suggesting potential to help reset the wound-healing cascade in complex wounds characterized by persistent inflammation.